文献速递胸部肿瘤放疗中枢神经肿瘤放疗

广泛期小细胞肺癌一线化免治疗后失败模式及巩固性胸部放疗的作用

Patterns of failure analysis and the role of consolidative thoracic radiotherapy in extensive‑stage small‑cell lung cancer treated with first‑line chemoimmunotherapy.
PubMed 文献 · Radiat Oncol · 2025-12-25

本研究纳入100例无脑转移的广泛期小细胞肺癌患者,均接受一线化疗联合免疫治疗,其中24例接受巩固性胸部放疗(cTRT)、76例未接受。失败模式分析显示胸腔内失败仍为主要失败模式,cTRT使胸腔内失败风险从60.0%降至29.4%,并延缓胸腔内和颅内进展;cTRT组中位总生存未达到,非cTRT组为14.1个月(HR=0.40,95%CI 0.22–0.70,P=0.01)。

要点

  • 化免治疗的广泛期小细胞肺癌中,胸腔内失败仍是最主要失败模式。
  • cTRT使胸腔内失败风险由60.0%降至29.4%,并延缓颅内进展。
  • cTRT组中位OS未达到,非cTRT组14.1个月(HR=0.40,P=0.01)。

核心结论

  • 在无脑转移的广泛期小细胞肺癌化免治疗患者中,cTRT显著减少胸腔内和颅内进展,并转化为无进展生存和总生存获益。

研究设计与样本

  • 单中心回顾性队列研究,纳入100例接受一线化免治疗的无脑转移广泛期小细胞肺癌患者,按是否接受cTRT分组(cTRT组24例,非cTRT组76例),采用Kaplan-Meier法和log-rank检验比较生存,并行单因素、多因素分析及倾向性评分匹配(PSM)平衡基线特征。

主要发现

  • 失败模式分析显示胸腔内失败仍为化免治疗广泛期小细胞肺癌的主要失败模式。
  • cTRT使胸腔内失败风险从60.0%降至29.4%,并在PSM前后均延缓胸腔内和颅内进展。
  • cTRT组中位总生存未达到,非cTRT组为14.1个月(HR=0.40,95%CI 0.22–0.70,P=0.01)。
  • cTRT组和非cTRT组3级肺炎发生率分别为9.7%和3%,未发生4级或5级肺炎。

关键数值与推荐

  • cTRT组胸腔内失败率为29.4%,非cTRT组为60.0%。
  • cTRT组中位OS未达到,非cTRT组为14.1个月(HR=0.40,95%CI 0.22–0.70,P=0.01)。
  • 3级肺炎发生率:cTRT组9.7%,非cTRT组3%;无4级或5级肺炎。

临床怎么用

  • 对化免治疗有效的无脑转移广泛期小细胞肺癌患者,可考虑联合cTRT以降低胸腔内失败和颅内进展风险并改善生存。
  • cTRT需关注3级肺炎风险,本研究未观察到4级或5级肺炎。

局限性

  • 本研究为回顾性研究,样本量有限(共100例,cTRT组仅24例),结果需前瞻性试验在免疫治疗时代进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of consolidative thoracic radiotherapy (cTRT) for extensive-stage small-cell lung cancer (ES-SCLC) remains controversial in the immunotherapy era, and the failure patterns in these patients require further exploration. This study aimed to investigate the failure pattern and the efficacy of cTRT in ES-SCLC patients treated with first-line chemoimmunotherapy. METHODS: Brain metastases (BMs)-free ES-SCLC patients treated with first-line chemoimmunotherapy were included and divided into different groups based on whether they received cTRT or not. Failure patterns were recorded. Kaplan-Meier survival curves and log-rank tests were used to compare the survival outcomes between the groups. Additionally, the survival benefits of cTRT were further evaluated through univariable and multivariate analyses. Propensity score matching (PSM) was used to balance the baseline characteristics. RESULTS: A total of 100 eligible BMs-free ES-SCLC patients were enrolled, with 24 (24.0%) in the cTRT group and 76 (76.0%) in the no-cTRT group. Failure pattern analyses revealed that intrathoracic failure remained the primary failure pattern in chemoimmunotherapy-treated ES-SCLC. The addition of cTRT to chemoimmunotherapy reduced the risk of intrathoracic failure (from 60.0% to 29.4%), and both intrathoracic and intracranial progression were delayed by cTRT before and after PSM. Moreover, cTRT significantly improved the overall survival (OS) of ES-SCLC patients compared to no-cTRT (median OS: not reached vs. 14.1 months; HR = 0.40, 95% CI: 0.22–0.70, P = 0.01). Grade 3 pneumonitis was recorded in 9.7% and 3% of patients in the cTRT group and the no-cTRT group, respectively. No cases of grade 4 or 5 pneumonitis occurred. CONCLUSIONS: In conclusion, this study characterized the failure patterns in BMs-free ES-SCLC patients treated with chemoimmunotherapy. cTRT significantly reduces intrathoracic and intracranial progression, and these benefits significantly translated into improved progression free survival and OS in chemoimmunotherapy-responsive ES-SCLC. These findings warrant the validation of prospective trials in the immunotherapy era.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lan A, Dong H, Gao J, et al. Patterns of failure analysis and the role of consolidative thoracic radiotherapy in extensive‑stage small‑cell lung cancer treated with first‑line chemoimmunotherapy. Radiat Oncol. 2025. PMID: 41449424. doi:10.1186/s13014-025-02783-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。